Multiomic Integration Prioritizes Guanfacine, Eltrombopag, Encorafenib as Alzheimer Repurposing Candidates
New data identifies specific cell targets in early Alzheimer's disease
This meta-analysis integrates multiomic data to identify cell-type-specific signatures and pharmacological targets in early Alzheimer's dise…
Researchers used advanced data integration to find specific cell types and pathways that could lead to new ways to treat early Alzheimer's d…
Encorafenib and Binimetinib Combination Therapy for Patients with BRAF Mutated Cutaneous Melanoma
Trial Shows Encorafenib and Binimetinib for Melanoma Patients
This trial evaluates the safety and efficacy of encorafenib and binimetinib in patients with resected stage IIB/IIC melanoma.
A clinical trial shows that a combination of encorafenib and binimetinib may improve recurrence-free survival for patients with specific mel…
Encorafenib plus binimetinib maintains quality of life in BRAF V600E-mutated thyroid cancer
Can new drugs help advanced thyroid cancer patients keep their daily life stable?
An uncontrolled phase 2 trial of 22 patients with BRAF V600E-mutated thyroid cancer found encorafenib plus binimetinib was associated with g…
A new drug combination helped advanced thyroid cancer patients maintain daily life stability without worsening their quality of life during …
Retrospective analysis identifies molecular correlates of benefit with encorafenib-based therapy in BRAF-mutant melanoma
Melanoma study finds tumor genetics and immune markers may predict treatment benefit
A retrospective exploratory analysis of the phase III COLUMBUS trial in 921 patients with BRAF V600E/K-mutant advanced melanoma found that s…
Patients with advanced melanoma who have higher tumor mutational burden or signs of immune system activity gain the most survival benefit fr…